文献速递肾小球疾病

肾小球疾病免疫抑制治疗的人群层面药物成本因实践模式变化而持续上升

The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究基于加拿大某省2000-2012年肾小球疾病病理数据库与行政数据库链接,随访至2013年,纳入2983例患者,评估免疫抑制药物年均每人成本变化。结果显示年均每人药物成本从205美元增至1394美元,增长6.8倍(P<0.001),主要驱动因素为吗替麦考酚酯、钙调神经磷酸酶抑制剂和利妥昔单抗的使用增加。

要点

  • 肾小球疾病免疫抑制药物年均每人成本14年间增长6.8倍。
  • 成本增长主要由新型高价药物(吗替麦考酚酯、钙调神经磷酸酶抑制剂、利妥昔单抗)驱动。
  • IgA肾病药物成本无显著变化,其他多种肾小球疾病成本显著上升。

核心结论

  • 肾小球疾病免疫抑制治疗的人群层面药物成本在14年间显著增加,主要因实践模式从较旧、较便宜药物转向较新、较昂贵药物。

研究设计与样本

  • 链接加拿大某省病理数据库(2000-2012年所有肾小球疾病病例)与肾脏及药物行政数据库,随访至2013年,纳入2983例患者,平均随访5.7年。

主要发现

  • 年均每人免疫抑制药物成本从205美元增至1394美元,增长6.8倍(P<0.001)。
  • 抗中性粒细胞胞浆抗体(ANCA)血管炎、局灶节段性肾小球硬化、狼疮肾炎、微小病变和膜性肾病的成本分别增长3.5-11.7倍(P≤0.004),IgA肾病无变化。
  • 吗替麦考酚酯、钙调神经磷酸酶抑制剂和利妥昔单抗的成本显著增加(P<0.001),其占药物成本比例从2000年的17.6%升至2013年的94.5%,使用患者比例从2.2%升至44.6%。
  • 硫唑嘌呤、环磷酰胺和泼尼松的成本仅轻微增加或下降。
  • 药物使用模式和成本贡献因肾小球疾病类型而异。

临床怎么用

  • 临床实践中应关注肾小球疾病免疫抑制治疗方案变化对药物成本的影响,为卫生政策策略和成本效果研究提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunosuppression (IS) is the main treatment for most types of glomerulonephritis (GN). Quantifying the cost of IS is necessary to ensure equitable access to therapies and optimal health outcomes, but the real-world cost of IS treatment for GN is largely unknown. We examined temporal changes in the population-level IS medication costs for GN over a 14-year period in a large Canadian province. METHODS: We linked a provincial pathology database (containing all GN cases from 2000 to 2012) with renal and medication administrative databases to capture clinical characteristics and IS medications, with follow-up until 2013. The primary outcome (mean IS medication cost per treated patient each year) was evaluated for trends over time. RESULTS: The cohort included 2983 GN patients followed for a mean of 5.7 years. The yearly per-patient medication cost increased 6.8-fold from $205 to $1394 (P < 0.001), with significant increases of 3.5-11.7-fold in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis, focal segmental glomerulosclerosis, lupus nephritis, minimal change disease and membranous nephropathy (P ≤ 0.004), but no change in immunoglobulin A (IgA) nephropathy. The cost of mycophenolate mofetil, calcineurin inhibitors and rituximab increased significantly (P < 0.001) such that in 2000 they accounted for 17.6% of medication costs and were used by 2.2% of patients, which increased to 94.5% and 44.6%, respectively, in 2013. The costs of azathioprine, cyclophosphamide and prednisone increased only slightly or decreased. Patterns of drug use and contribution to cost varied by type of GN. CONCLUSIONS: These are the first population-level estimates of the IS treatment costs for GN, and demonstrate a striking increase due to changing practice patterns from older, cheaper medications to newer, more expensive therapies. These results provide important information to guide future health policy strategies and cost-effectiveness research in glomerular diseases.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Barbour S, Lo C, Espino-Hernandez G, et al. The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice. Nephrol Dial Transplant. 2018. PMID: 29106654. doi:10.1093/ndt/gfx185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。